N/A
Completed N=111
Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis
Osteoarthritis, Knee
Source: ClinicalTrials.gov NCT02588872 ↗
Enrolled (actual)
111
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: International Knee Documentation Committee Score (IKDC — 65.5; 55.8 units on a scale
Summary
In this, prospective, double-blind study, patients with mild to moderate symptomatic knee osteoarthritis will be randomized to receive either a series of leukocyte poor, platelet-rich plasma or hyaluronic acid injections under ultrasound guidance. Clinical data in the form of subjective outcome measures will be collected pre-treatment and at four time intervals across a 1-year period. Synovial fluid will also collected for analysis of pro- and anti-inflammatory markers pre-treatment, and at 12 and 24 weeks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY International Knee Documentation Committee Score (IKDC |
65.5; 55.8 | — |
| SECONDARY Visual Analogue Scale (VAS) |
57.3; 44 | — |
| SECONDARY Western Ontario and McMaster Universities Arthritis Index |
4; 3.02 | — |
| SECONDARY Lysholm Knee Score |
55.8; 65.5 | — |
| SECONDARY Biologic Testing of Synovial Fluid Via ELISA Assays |
0.14; 0.34 | — |
Eligibility Criteria
Inclusion Criteria
- 18-80 years old
- Mild to moderate unilateral, symptomatic osteoarthritis of the knee
- No recent (within 3 months) intra-articular intervention to the affected knee
Exclusion Criteria
- Knee instability
- Varus/Valgus alignment >5 degrees
- Bilateral knee osteoarthritis
- Systemic inflammatory arthropathy
- Known history of anemia, coagulopathy, or present use of blood thinners
Data sourced from ClinicalTrials.gov (NCT02588872). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.